Significant Ownership of Adimab, LLC

Manager identity
Signature and title
/s/ Philip Chase - Philip Chase, Chief Executive Officer
Location
Lebanon, NH
Large-stake snapshot
Schedule 13D/G read
Recent SEC Schedule 13D/G filings for Adimab, LLC, focused on large-stake beneficial ownership disclosures and amendments.

Follow Filing Activity

Follow Adimab, LLC and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Adimab, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IVVD Invivyd, Inc. Common Stock, $0.0001 par value per share 7.3% $47,210,856 -$448,106 20,262,170 -0.94% Adimab, LLC 23 Dec 2025

Schedules 13D/G Reported by Adimab, LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .